We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-3.89%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.3B
AUM Growth
-$140M
Cap. Flow
+$106M
Cap. Flow %
4.61%
Top 10 Hldgs %
42.59%
Holding
80
New
11
Increased
12
Reduced
36
Closed
4

Top Buys

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$37.7M
2
DXCM icon
DexCom
DXCM
+$37.6M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$34.7M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$33.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$31.7M

Top Sells

Rank Stock Value
1
ONEM
1Life Healthcare
ONEM
+$38.9M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$38.2M
3
PLRX icon
Pliant Therapeutics
PLRX
+$27.1M
4
AKRO
Akero Therapeutics
AKRO
+$26.2M
5
REPL icon
Replimune Group
REPL
+$24.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.78%
2 Industrials 1.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TOI icon
76
The Oncology Institute
TOI
$535M
$216K 0.01%
318,082
-1,265,076
-80% -$1.61M
BVS icon
77
Bioventus
BVS
$817M
– –
-535,950
Closed -$1.4M
IONS icon
78
Ionis Pharmaceuticals
IONS
$8.99B
– –
-266,187
Closed -$10.1M
RVMD icon
79
Revolution Medicines
RVMD
$39.6B
– –
-625,000
Closed -$14.9M
ONEM
80
DELISTED
1Life Healthcare
ONEM
– –
-2,326,625
Closed -$38.9M
1 2 3
4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q1 2023 Portfolio in Review

As of Q1 2023, Redmile Group held 80 positions worth $2.3B, down 5.7% from $2.44B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Redmile Group deployed $106M of net new capital in Q1 2023, opening 11 new positions and adding to 12 existing holdings. Its largest new stake was CATALENT, INC.: 610,304 shares worth $40.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $38.2M trimmed.

  • Redmile Group's largest Q1 2023 buy was CATALENT, INC.: 610,304 shares worth $40.1M.
  • Redmile Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2023, an estimated $33.2M increase.
  • Redmile Group's biggest Q1 2023 reduction was Xenon Pharmaceuticals, cutting an estimated $38.2M.
  • Redmile Group fully exited 1Life Healthcare in Q1 2023, selling an estimated $38.9M.
  • Redmile Group's ten largest holdings make up 43% of its $2.3B portfolio in Q1 2023.
  • Redmile Group opened 11 new positions and closed 4 in Q1 2023.
  • Redmile Group's portfolio value fell 5.7% quarter-over-quarter to $2.3B.

Based on Redmile Group's 13F filing for Q1 2023, filed 15 May 2023.